Supramolecular interactions in cocrystals of benzoic acid derivatives with selective COX-2 inhibitor etoricoxib

被引:0
|
作者
Ma, Yu Heng [1 ]
Yang, Kang [1 ]
Qian, Yan Ling [1 ]
Hong, Wei Pu [1 ]
Zhang, Kai Yue [1 ]
Tao, Zhen Wei [1 ]
Meng, Hui [1 ]
Ma, Wen Jing [1 ]
机构
[1] Chuzhou Univ, Sch Mat Sci & Chem Engn, Chuzhou 239000, Anhui, Peoples R China
来源
ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY | 2024年 / 80卷
关键词
crystal structure; etoricoxib; cocrystal; hydrogen bonds; energy framework; benzoic acid; COX-2; inhibitor; CRYSTALEXPLORER; PROGRAM; SALTS;
D O I
10.1107/S2053229624006193
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The structures of three 1:1 cocrystal forms of etoricoxib {ETR; systematic name: 5-chloro-2-(6-methylpyridin-3-yl)-3-[4-(methylsulfonyl)phenyl]pyridine, C18H15-ClN2O2S} have been synthesized and characterized by single-crystal X-ray diffraction; these are etoricoxib-benzoic acid (1/1), C18H15ClN2O2S center dot C7H6O2 (ETR-Bz), etoricoxib-4-fluorobenzoic acid (1/1), C18H15ClN2O2S center dot C7H5FO2 (ETR-PFB), and etoricoxib-4-nitrobenzoic acid (1/1), C18H15ClN2O2S center dot-C7H5NO4 (ETR-PNB). Powder X-ray diffraction and thermal differential scanning calorimetry-thermogravimetry (DSC-TG) techniques were also used to characterize these multicomponent systems. Due to the influence of the corresponding acids, ETR shows different conformations. Furthermore, the energetic contributions of the supramolecular motifs have been established by energy framework studies of the stabilizing interaction forces and are consistent with the thermal stability of the cocrystals.
引用
收藏
页码:366 / +
页数:25
相关论文
共 50 条
  • [1] Characterization of etoricoxib, a novel, selective COX-2 inhibitor
    Dallob, A
    Hawkey, CJ
    Greenberg, H
    Wight, N
    De Schepper, P
    Waldman, S
    Wong, P
    DeTora, L
    Gertz, B
    Agrawal, N
    Wagner, J
    Gottesdiener, K
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06) : 573 - 585
  • [2] Etoricoxib: A highly selective COX-2 inhibitor
    Martina, SD
    Vesta, KS
    Ripley, TL
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (05) : 854 - 862
  • [3] Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor
    Patrignani, P
    Capone, ML
    Tacconelli, S
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (02) : 265 - 284
  • [4] Polymorphs and hydrates of Etoricoxib, a selective COX-2 inhibitor
    Grobelny, Pawel
    Mukherjee, Arijit
    Desiraju, Gautam R.
    CRYSTENGCOMM, 2012, 14 (18): : 5785 - 5794
  • [5] Primary stabbing headache can be responsive to etoricoxib, a selective COX-2 inhibitor
    O'Connor, M. B.
    Murphy, E.
    Phelan, M. J.
    Regan, M. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (01) : E1 - E1
  • [6] Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis
    Arendt-Nielsen, Lars
    Egsgaard, Line Lindhardt
    Petersen, Kristian Kjaer
    PAIN, 2016, 157 (08) : 1634 - 1644
  • [7] Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective inhibitor etoricoxib
    Curtis, Sean P.
    Ko, Amy T.
    Bolognese, James A.
    Cavanaugh, Paul F., Jr.
    Reicin, Alise S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (12) : 2365 - 2374
  • [8] Clinical pharmacology of the selective COX-2 inhibitor
    Burian, M
    Geisslinger, G
    ORTHOPADE, 2003, 32 (12): : 1078 - +
  • [9] Etodolac: An overview of a selective COX-2 inhibitor
    Jones R.A.
    InflammoPharmacology, 1999, 7 (3) : 269 - 275
  • [10] Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats
    Citraro, Rita
    Leo, Antonio
    Marra, Rosario
    De Sarro, Giovambattista
    Russo, Emilio
    BRAIN RESEARCH BULLETIN, 2015, 113 : 1 - 7